Drug Approval
Name: Camzyos
Active Ingredient: mavacamten
Indications: To treat certain classes of obstructive hypertrophic cardiomyopathy
Approval Date: 4/28/2022
Company: MyoKardia, Inc., a wholly-owned subsidiary of Bristol Myers Squibb
More: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214998s000lbl.pdf